Stalicla secures chf 2 million financing led by addex therapeutics to advance precision medicine neurodevelopmental disorder programs

Press release stalicla secures chf 2 million financing led by addex therapeutics to advance precision medicine neurodevelopmental disorder programs geneva, switzerland – june 30, 2025 – stalicla sa, a geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a chf 2 million financing led by addex therapeutics. this financing will sustain operations and program development in neurodevelopmental disorders as stalicla prepares for its upcoming series c and the partnering of key programs.
ADXN Ratings Summary
ADXN Quant Ranking